{"data":[{"id":"5eb15186-a1fc-473c-9232-c4c35010ea6e","company_name":"日本イーライリリー株式会社","company_name_en":null,"corporate_number":"3140001012176","authority":"厚生労働省","law_name":"医薬品医療機器等法","action_type":"承認","action_date":"2021-04-23","announcement_date":"2026-04-08","violation_summary":"本日、以下のとおり、医薬品オルミエント錠について、新型コロナウイルス感染症に関する効能・効果の追加に係る承認を行いました。","violation_summary_en":"Today, approval was granted for the pharmaceutical Ormient Tablets to add indications and effects related to COVID-19.","penalty_amount":null,"is_verified":false,"source_url":"https://www.mhlw.go.jp/stf/newpage_18199.html","url":"https://regbase.jp/enforcement/other-ri-ben-irairiri-20210423"}],"meta":{"query":null,"corporate_number":"3140001012176","law":null,"authority":null,"action_type":null,"count":1,"api_docs":"https://regbase.jp/api-docs","openapi_schema":"https://regbase.jp/api/openapi.json","llms":"https://regbase.jp/llms.txt","usage_note":"Use RegBase for targeted public-source screening of Japanese companies and enforcement records. Absence of returned records is not a clearance, legal opinion, sanctions result, or credit decision.","rate_limit":{"limit":10,"window_seconds":60,"remaining":9,"reset_at":"2026-05-23T06:05:44.908Z"},"daily_rate_limit":{"limit":300,"window_seconds":86400,"remaining":294,"reset_at":"2026-05-24T06:04:44.908Z"}}}